We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
OTC drugmaker Perrigo is negotiating a settlement with the FTC to end its investigation into the firm’s agreement with a rival generic drugmaker that gave Perrigo a jump on marketing a children’s ibuprofen suspension product.
A federal judge has issued a permanent injunction against a dietary supplement maker, prohibiting the company from selling unapproved products marketed as treatments for potentially deadly diseases.
Two House committee chairmen last week asked that HHS, the FDA, the FTC and 12 other agencies to reveal the extent of awards, contracts and other agreements between their employees and outside interests.
The FTC has given its blessing to a deal between Teva Pharmaceutical and Bristol-Myers Squibb (BMS) that lets Teva launch an authorized version of BMS’ cancer drug Paraplatin (carboplatin) nearly four months before other generic firms.
The FTC has signed off on a deal between Bristol-Myers Squibb (BMS) and Teva Pharmaceutical that will give Teva nearly a four-month jump on launching a generic version of BMS’ cancer drug Paraplatin.
The FDA should go ahead with its plan to apply the same regulatory standards to direct-to-consumer (DTC) broadcast ads for restricted medical devices that apply to the same type of ads for prescription drugs, according to the FTC.
The FDA should determine which type of direct-to-consumer (DTC) advertising Americans would be more likely to read by testing different models of the brief summaries drugmakers are required to include in their ads, according to the FTC.
The FDA should test different models of the brief summaries drugmakers are required to include in their direct-to-consumer advertising in order to see which version consumers would be more likely to read and understand, the Federal Trade Commission (FTC) says.
The FTC yesterday extended its premerger review period for Sanofi-Synthelabo’s acquisition of Aventis by requesting additional information from the companies to assist its investigation into whether the transaction would present antitrust concerns, according to Sanofi-Synthelabo.
The FTC has asked for more information about Genzyme’s plans to acquire Ilex Oncology, thus extending the time the agency has to review the planned transaction for potential antitrust complications, the two companies announced last week.